Drug Profile
Research programme: adoptive cell therapies - MiNK Therapeutics
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Agenus
- Developer MiNK Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer